Relmada Therapeutics, Inc. Board of Directors

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

Ms. Gina DiGuglielmo

Ms. Gina DiGuglielmo

VP & Head of Clinical Operations

Mr. John Hixon

Mr. John Hixon

Head of Commercial

Mr. Charles S. Ence CPA, M.B.A.

Mr. Charles S. Ence CPA, M.B.A.

Chief Accounting & Compliance Officer

Dr. Marco Pappagallo M.D.

Dr. Marco Pappagallo M.D.

Chief Clinical Officer

Dr. Andrew Cutler

Dr. Andrew Cutler

Senior Clinical Development Advisor

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.